Tourette Syndrome Treatment Market Opportunities in North America and Europe 2019 – Growth by Latest Trends, Technologies, Use of Drugs, Advancement Contributing Top Vendor Landscape By 2026
Tourette syndrome is a rare and severe neurological disorder which causes tics. Tic is a repetitive involuntary movements, sudden, no rhythmic motor movements. It occurs due to the mutations of the SLITRK1 gene, which plays an important role in development of nerve cells. This syndrome usually occurs among the people of age between 2-15 years. There are four types of tics: motor tics (uncontrolled body movements), vocal tics (outburst of sound), simple tics (includes few parts of body), and complex tics (contains several parts of body). Tourette’s syndrome is related to other additional neurobehavioral problems like impulsivity, problems with reading and writing, obsessive-compulsive symptoms. It can be treated with neuroleptics; haloperidol and pimozide are largely used medicines for Tourette syndrome. Other medications such as guanfacine and clonidine are useful to treat the severity of tics.
Get FREE Sample PDF (Including COVID-19 Impact Analysis, Full TOC, Tables and Figures) of Tourette Syndrome Treatment, https://www.coherentmarketinsights.com/insight/request-sample/2642
Tourette Syndrome Treatment Market Drivers
Drug approvals by regulatory authorities is expected to boost the global tourette syndrome treatment market growth. For instance, in October 23, 2017, Neurocrine Biosciences Inc. announced that the Food Drug and Administration approved valbenazine orphan drug designation to treat the pediatric patients with the Tourette syndrome. Furthermore, in September 19, 2017, Teva Pharmaceutical Industries and Nuvelution Pharma announced their partnership to develop AUSTEDO (deutetrabenazine) tablets for the treatment of tics which is associated to tourette syndrome in pediatric patients in the U.S. This partnership will drive the development of Austedo (deutetrabenazine) in Tourette syndrome by bringing new treatment options more quickly which are more necessary for the affected young patients. These factors are expected to propel the global Tourette syndrome treatment market growth.
Moreover, there are several investigations made for the treatment of Tourette syndrome. For instance, in March 2019, Wesley Medical Research was partnering with the University of Sydney in Australia which carried the clinical trial to investigate whether the medical cannabis could be used to treat the individuals with Tourette syndrome. This trial will help examine efficacy and safety of cannabinoids on tic frequency as well as the psychiatric symptoms associated with Tourette syndrome.
Need a discount?
Note: *The discount is offered on the Standard Price of the report.
Request discount for this report @ https://www.coherentmarketinsights.com/insight/request-discount/2642
Furthermore, the acquisitions of companies drive the growth of the Tourette syndrome treatment market. For instance, on August 14, 2018, Emalex Biosciences acquired the Psyadon Pharmaceuticals and the rights to develop, register and market ecopipam, the investigational drug of Psyadon Pharmaceuticals, which is used to treat the Tourette syndrome in children less than 16 years of age.
Tourette Syndrome Treatment Market Regional Analysis
On the basis of region, the Tourette syndrome market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the Tourette syndrome treatment market due to presence of large number of key players like Otsuka Holdings Co., Ltd, AstraZeneca PLC, Catalyst Pharmaceutical Parteners, Inc. In terms of revenue, U.S. contributes the major share of this syndrome treatment market. According to the National Institute Of Neurological Disorders And Stroke(NIH), it is estimated that around 2,00,000 Americans have the most severe form of Tourette syndrome and as many as one in 100 shows milder or less complex symptoms such as vocal tics.
Tourette Syndrome Treatment Market Restraints
Withdrawal of the drugs in late stages of clinical trials has hampered the global Tourette syndrome treatment market growth. For instance, on December 12, 2018, Neurocrine Biosciences revealed that the phase IIb study of valbenazine did not meet the primary endpoint of reducing the tic severity in young people in moderate to severe form of diseases.
Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2642
Tourette Syndrome Treatment Market Key Players
Some of the major players operating in the global Tourette syndrome treatment market include Neurocrine Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Apotex, Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, Torrent Pharmaceuticals Limited and Eli Lilly Pharmaceuticals.
Tourette syndrome treatment Market Taxonomy
On the basis of drug class, the global Tourette syndrome treatment market is segmented into:
- Antiadrenergic Agents
- Antipsychotic Agents
- Atypical Antipsychotics
- Carbonic Anhydrase Inhibitor Anticonvulsants
On the basis of distribution channel, the global Tourette syndrome treatment market is segmented into:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
On the basis of region, the global Tourette syndrome treatment market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
Other Related Reports:
Epo Biomarkers Market, by Biomarker Type (Recombinant Human Erythropoietin, Erythropoietin Alfa, Erythropoietin Beta, Erythropoietin Zeta, Erythropoietin Theta, and Darbepoietin Alfa), by Application (End-stage Renal Disorder, Cancer, Rheumatoid Arthritis, AIDS, Myelodysplastic Syndrome, Neurology, Hematology, and Others), by End User (Diagnostic Centers, Hospitals, and Ambulatory Care and Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy (Stem Cell Therapy, Substrate Reduction Therapy, Others)), By Indication (Gaucher’s Disease, Fabry Disease, Pompe’s Syndrome, Mucopolysaccharidosis, Others), By End User (Hospitals, Clinics), and By Region (North America Latin America Europe Asia Pacific Middle East Africa) – Size, Share Outlook, and Opportunity Analysis, 2019 – 2027
Carrier Screening Market, by Test Type (Expanded Carrier Screening and Targeted Disease Carrier Screening), By Disease Type (Cystic Fibrosis, Sickle Cell Disease, Spinal Muscular Atrophy, Fragile X Syndrome, Thalassemia, and Others), By End User (Hospitals, Reference Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire